MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ABBOTT INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Abbott India Quarterly Results 
(KNOL)
Here are the latest quarterly results of Abbott India. For more details, see the Abbott India financial fact sheet and Abbott India share price and chart. For a sector overview, read our pharmaceuticals sector report.
Abbott India Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,154 | 7,147 | 9,310 | 8,815 | 7,884 | 8,449 | 9,797 | 9,477 | |
| Other income | Rs m | 155 | 159 | 151 | 190 | 586 | 218 | 245 | 376 | |
| Turnover | Rs m | 7,309 | 7,306 | 9,460 | 9,005 | 8,470 | 8,667 | 10,043 | 9,853 | |
| Expenses | Rs m | 6,526 | 6,531 | 7,296 | 7,182 | 6,817 | 7,336 | 7,857 | 8,012 | |
| Gross profit | Rs m | 629 | 616 | 2,013 | 1,633 | 1,066 | 1,114 | 1,940 | 1,465 | |
| Depreciation | Rs m | 38 | 40 | 40 | 42 | 40 | 40 | 41 | 40 | |
| Interest | Rs m | 20 | 5 | 6 | 5 | 22 | 6 | 5 | 4 | |
| Profit before tax | Rs m | 725 | 731 | 2,118 | 1,776 | 1,591 | 1,286 | 2,140 | 1,797 | |
| Tax | Rs m | 304 | 248 | 743 | 622 | 590 | 462 | 763 | 627 | |
| Profit after tax | Rs m | 421 | 483 | 1,375 | 1,154 | 1,001 | 824 | 1,377 | 1,171 | |
| Gross profit margin | % | 8.8 | 8.6 | 21.6 | 18.5 | 13.5 | 13.2 | 19.8 | 15.5 | |
| Effective tax rate | % | 42.0 | 34.0 | 35.1 | 35.0 | 37.1 | 35.9 | 35.7 | 34.9 | |
| Net profit margin | % | 5.9 | 6.8 | 14.8 | 13.1 | 12.7 | 9.8 | 14.1 | 12.4 | |
| Diluted EPS | Rs | 19.8 | 22.7 | 64.7 | 54.3 | 47.1 | 38.8 | 64.8 | 55.1 | |
| Diluted EPS (TTM) | Rs | 130.2 | 118.1 | 147.5 | 161.5 | 188.8 | 204.9 | 205.0 | 205.7 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Abbott India 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ORCHID PHARMA LTD LUPIN ELDER PHARMA PLETHICO PHARMA J.B.CHEMICALS
Compare ABBOTT INDIA With: ORCHID PHARMA LTD LUPIN ELDER PHARMA PLETHICO PHARMA J.B.CHEMICALS
Compare ABBOTT INDIA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Elections or Game of Thrones: What Excites You More?(Podcast)
As the TV war in Game of Thrones is set to conclude, we in India, are amidst our own battle for power - the 2019 Elections.
Views on news
ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
My Master Series on How to Trade Election 2019(Profit Hunter)
Apr 16, 2019For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...
Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)
Apr 17, 201920% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.
The Best Trading Strategy in the World(Profit Hunter)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
Election Series: Why 'Liquor' is so Important to the Elections(The 5 Minute Wrapup)
Apr 19, 2019When elections come around, liquor flows like water and everyone gets drunk with power...what does this mean for liquor stocks? Read one to find out from our very own election trading analyst, Vijay Bhambwani.
More|
| |
ABBOTT INDIA SHARE PRICE
Apr 26, 2019 (Close)
TRACK ABBOTT INDIA
- Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ABBOTT INDIA
ABBOTT INDIA - ACTAVIS COMPARISON
COMPARE ABBOTT INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.